Wiley partners with multiple AI firms to integrate content into agentic AI and Claude platforms.
“Healthcare AI: Where Partnerships and Proprietary Data Converge The gap between published research and clinical practice has persisted for decades. Every content partnership that puts peer- reviewed evidence directly into the physician’s workflow makes that gap narrower. This one (Wiley) makes it meaningfully so. Daniel Nadler · CEO, OpenEvidence “ May 2025 Wiley partners with AWS Lifesciences to integrate peer- reviewed research into Agentic AI framework Jul 2025 Wiley partners with Anthropic to integrate trusted, peer-reviewed scholarly content directly into the Claude AI platform— first publisher to do so Nov 2025 Wiley executes strategic partnership with IQVIA to expand Clinical Outcomes Assessment go-to-market Mar 2026 Wiley executes multi-year agreement with OpenEvidence for research at point of care, holds equity stake Unlocking Value in Existing Portfolio: Clinical Outcomes Assessments ▸Hidden Gems: Wiley has one of the world's largest collections of COAs — patient-reported outcomes and fragmented data from clinical trials ▸Demand is ever-increasing: as clinical trials undergo fundamental transformation requiring these instruments for regulatory and efficiency purposes ▸New growth pathway: COA revenue rose from $700K (FY21) to $11M (FY26), up 68% from $6.5M in prior year; strong growth expected. IQVIA is Wiley's GTM partner ▸More Hidden Gems: Working to uncover other opportunities within our extensive portfolio Mar 2026 Wiley partners with Microsoft to bring Wiley res”